Moderna Reportedly Plunges Over 17% Following Disappointing Melanoma Vaccine Data

Moderna $MRNA reportedly fell more than 17%, with shares declining as much as 26% intraday, following claims of disappointing Phase 3 results for its experimental cancer vaccine.
The reported data suggested a 42% reduction in the risk of melanoma recurrence or death, compared with a previously reported 49% reduction in an earlier study.
However, results from different trials cannot be directly compared without considering study design, patient populations and statistical uncertainty. The claimed data leak and Phase 3 findings also require official confirmation.
The report estimates $17 billion in lost market value and says shares remain up more than 570% this year. Both figures require verification against current trading data.